Skip to main content

Market Overview

Benzinga's Top Upgrades, Downgrades For January 2, 2019

Share:

Top Upgrades

  • Baird upgraded SunTrust Banks, Inc. (NYSE: STI) from Neutral to Outperform. SunTrust shares fell 1 percent to $49.96 in pre-market trading.
  • Stephens upgraded CBS Corporation (NYSE: CBS) from Equal-Weight to Overweight. CBS shares rose 0.1 percent to $43.76 in pre-market trading.
  • UBS upgraded Caesars Entertainment Corporation (NASDAQ: CZR) from Sell to Neutral. Caesars rose 0.2 percent to $6.80 in pre-market trading.
  • Susquehanna upgraded Crocs, Inc. (NASDAQ: CROX) from Neutral to Positive. Crocs shares rose 0.3 percent to $26.05 in pre-market trading.
  • Citigroup upgraded Zimmer Biomet Holdings Inc (NYSE: ZBH) from Neutral to Buy. Zimmer Biomet fell 0.7 percent to $103.00 in pre-market trading.
  • RBC Capital upgraded Wells Fargo & Co (NYSE: WFC) from Underperform to Sector Perform. Wells Fargo shares fell 1.3 percent to $45.50 in pre-market trading.
  • Analysts at JP Morgan upgraded Sirius XM Holdings Inc (NASDAQ: SIRI) from Underweight to Overweight. Sirius XM shares rose 0.4 percent to $5.73 in pre-market trading.
  • Morgan Stanley upgraded Baxter International Inc (NYSE: BAX) from Equal-Weight to Overweight. Baxter shares fell 0.8 percent to $65.30 in pre-market trading.
  • Evercore ISI Group upgraded Stryker Corporation (NYSE: SYK) from In-Line to Outperform. Stryker shares gained 1.12 percent to close at $156.75 on Monday.
  • Citigroup upgraded Estee Lauder Companies Inc (NYSE: EL) from Neutral to Buy. Estee Lauder shares rose 1.2 percent to close at $130.10 on Monday.

 

Top Downgrades

  • Citigroup downgraded Abbott Laboratories (NYSE: ABT) from Neutral to Sell. Abbott shares dropped 2.7 percent to $70.39 in pre-market trading.
  • Morgan Stanley downgraded Hologic, Inc. (NASDAQ: HOLX) from Equal-Weight to Underweight. Hologic shares fell 4 percent to $39.45 in pre-market trading.
  • Raymond James downgraded Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Market Outperform to Market Perform. Vertex Pharmaceuticals shares gained 2.66 percent to close at $165.71 on Monday.
  • JP Morgan downgraded AFLAC Incorporated (NYSE: AFL) from Overweight to Neutral. Aflac shares dropped 2.1 percent to $44.60 in pre-market trading.
  • Citigroup downgraded Medtronic PLC (NYSE: MDT) from Buy to Neutral. Medtronic shares fell 1.1 percent to $90.00 in pre-market trading.
  • Raymond James downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Market Outperform to Market Perform. Biomarin Pharmaceutical shares dropped 2.3 percent to $83.16 in pre-market trading.
  • JP Morgan downgraded Flex Ltd (NASDAQ: FLEX) from Overweight to Neutral. Flex shares fell 0.13 percent to close at $7.61 on Monday.
  • Cowen & Co. downgraded Akamai Technologies, Inc. (NASDAQ: AKAM) from Outperform to Market Perform. Akamai Technologies shares closed at $61.08 on Monday.
  • Baird downgraded Henry Schein, Inc. (NASDAQ: HSIC) from Outperform to Neutral. Henry Schein shares fell 2.5 percent to $76.60 in pre-market trading.
  • Bank of America downgraded CyrusOne Inc (NASDAQ: CONE) from Buy to Neutral. CyrusOne shares rose 1.21 percent to close at $52.88 on Monday.

 

Top Initiations

  • Analysts at Canaccord Genuity initiated coverage on Paratek Pharmaceuticals Inc (NASDAQ: PRTK) with a Buy rating. The price target for Paratek Pharmaceuticals is set to $14. Paratek Pharmaceuticals closed at $5.13 on Monday.
  • Barclays initiated coverage on Moderna Inc (NASDAQ: MRNA) with an Overweight rating. The price target for Moderna is set to $20. Moderna shares closed at $15.27 on Monday.
  • Leerink Swann initiated coverage on Medidata Solutions Inc (NASDAQ: MDSO) with a Market Perform rating. Medidata shares closed at $67.42 on Monday.
  • Canaccord Genuity initiated coverage on Insmed Incorporated (NASDAQ: INSM) with a Buy rating. The price target for Insmed is set to $20. Insmed shares closed at $13.12 on Monday.
  • Morgan Stanley initiated coverage on Moderna Inc (NASDAQ: MRNA) with an Overweight rating. The price target for Moderna is set to $29. Moderna shares closed at $15.27 on Monday.
 

Related Articles (ABT + AFL)

View Comments and Join the Discussion!

Posted-In: Initiations top upgradesUpgrades Downgrades Initiation Pre-Market Outlook Analyst Ratings

Latest Ratings

StockFirmActionPT
FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com